Copley Gets a New Life
Executive SummaryAfter a few volatile years, Copley Pharmaceutical has a new management team, which is gearing up the generics company for growth. Hoechst, which owns 51% of Copley, has said it wants to get out of the generics business and is letting the new management decide on an exit strategy. New CEO Daniel Korpolinski (previously head of CoCensys), believes that Copley's relationships with top national drug store chains remain strong and will help its revival.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.